These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1204 related articles for article (PubMed ID: 23453151)

  • 41. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
    Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
    Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
    Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.
    Wang TJC; Wu CC; Jani A; Estrada J; Ung T; Chow DS; Soun JE; Saad S; Qureshi YH; Gartrell R; Saadatmand HJ; Saraf A; Garrett MD; Grubb C; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; McKhann GM
    Pract Radiat Oncol; 2016; 6(5):306-314. PubMed ID: 26952813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients.
    Okumus NO; Gursel B; Meydan D; Ozdemir O; Odabas E; Gonullu G
    Ann Saudi Med; 2012; 32(3):250-5. PubMed ID: 22588435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
    Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
    Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
    Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
    Minniti G; De Sanctis V; Muni R; Rasio D; Lanzetta G; Bozzao A; Osti MF; Salvati M; Valeriani M; Cantore GP; Maurizi Enrici R
    J Neurooncol; 2009 Jan; 91(1):95-100. PubMed ID: 18758912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
    Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
    Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
    Rhee DJ; Kong DS; Kim WS; Park KB; Lee JI; Suh YL; Song SY; Kim ST; Lim DH; Park K; Kim JH; Nam DH
    Clin Neurol Neurosurg; 2009 Nov; 111(9):748-51. PubMed ID: 19716649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience.
    Caloglu M; Yurut-Caloglu V; Karagol H; Bayir-Angin G; Turan FN; Uzal C
    J BUON; 2009; 14(2):211-8. PubMed ID: 19650168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
    Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
    Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
    Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.